Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy
- 1 January 2002
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 282 (1) , H58-H65
- https://doi.org/10.1152/ajpheart.2002.282.1.h58
Abstract
Targeted disruption of the gene for natriuretic peptide receptor-A (NPR-A) worsens pulmonary hypertension and right ventricular hypertrophy during hypoxia, but its effect on left ventricular mass and systemic pressures is not known. We examined the effect of 3 wk of hypobaric hypoxia (0.5 atm) on right and left ventricular pressure and mass in mice with 2 (wild type), 1, or 0 copies of Npr1, the gene that encodes for NPR-A in mice. Under normoxic conditions, right ventricular peak pressure (RVPP) was greater in 0 than in 2 copy mice, but there were no genotype-related differences in carotid artery PP (CAPP). The left ventricular free wall weight-to-body weight (LV/body wt) ratio was greater in 0 than in 2 copy mice and there was a trend toward a greater right ventricular weight-to-body weight (RV/body wt) ratio. Three weeks of hypoxia increased RVPP and RV/body wt in all genotypes. The increase in RVPP was similar in all genotypes (11–14 mmHg), but the hypoxia-induced increase in RV/body wt was more than twice as great in 0 copy mice than in 2 copy mice (1.11 ± 0.06 to 2.65 ± 0.46 vs. 0.96 ± 0.04 to 1.4 ± 0.09, P < 0.05). Chronic hypoxia had no effect on CAPP in any genotype and did not effect LV/body wt in 1 or 2 copy mice, but increased LV/body wt 41% in 0 copy mice. We conclude that absent expression of NPR-A worsens right ventricular hypertrophy and causes left ventricular hypertrophy during exposure to chronic hypoxia without increasing pulmonary or systemic arterial pressure responses.Keywords
This publication has 37 references indexed in Scilit:
- Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A–deficient miceJournal of Clinical Investigation, 2001
- Natriuretic Peptide Receptor-A Negatively Regulates Mitogen-Activated Protein Kinase and Proliferation of Mesangial Cells: Role of cGMP-Dependent Protein KinaseBiochemical and Biophysical Research Communications, 2000
- Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.Journal of Clinical Investigation, 1998
- Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular bedsGeneral Pharmacology: The Vascular System, 1997
- Atrial Natriuretic Peptide Inhibits Mitogen-activated Protein Kinase through the Clearance ReceptorPublished by Elsevier ,1996
- Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells.Journal of Clinical Investigation, 1990
- Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.Journal of Clinical Investigation, 1990
- Time course of cardiopulmonary responses to high altitude in susceptible and resistant rat strainsRespiration Physiology, 1987
- Physiological Role of Silent Receptors of Atrial Natriuretic FactorScience, 1987
- Probable strain differences of rats in susceptibilities and cardiopulmonary responses to chronic hypoxiaRespiration Physiology, 1983